Barclays PLC increased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 301.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,593 shares of the company's stock after acquiring an additional 39,506 shares during the quarter. Barclays PLC owned approximately 0.15% of Harrow worth $2,365,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Harrow during the 3rd quarter valued at approximately $487,000. Wellington Management Group LLP grew its stake in shares of Harrow by 3.6% during the 3rd quarter. Wellington Management Group LLP now owns 103,179 shares of the company's stock worth $4,639,000 after purchasing an additional 3,612 shares during the period. State Street Corp increased its holdings in Harrow by 2.2% in the third quarter. State Street Corp now owns 730,973 shares of the company's stock valued at $32,865,000 after buying an additional 15,554 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Harrow during the third quarter worth approximately $606,000. Finally, Braidwell LP grew its stake in Harrow by 47.9% in the 3rd quarter. Braidwell LP now owns 439,638 shares of the company's stock valued at $19,766,000 after acquiring an additional 142,450 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.
Harrow Stock Performance
NASDAQ HROW traded up $1.23 during trading on Thursday, reaching $35.06. The company's stock had a trading volume of 194,785 shares, compared to its average volume of 499,504. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a twelve month low of $9.13 and a twelve month high of $59.23. The business's fifty day moving average price is $43.40 and its 200-day moving average price is $36.99. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -37.30 and a beta of 0.69.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on HROW shares. B. Riley cut their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research report on Wednesday, December 4th. Lake Street Capital lifted their price target on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. Finally, Craig Hallum increased their price objective on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th.
Read Our Latest Report on HROW
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
